LYMPHOSEEK

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland, Spain, UK.

Active ingredients

The drug LYMPHOSEEK contains one active pharmaceutical ingredient (API):

1	Technetium ⁹⁹ᵐTc tilmanocept UNII MDU8BQ474H - TILMANOCEPT
	Technetium ⁹⁹ᵐTc tilmanocept is a receptor-targeted radiopharmaceutical that is designed to rapidly transit lymphatic vessels; it biotargets, accumulates, and is retained in primary, key predictive, draining lymph nodes (sentinel lymph nodes).
	Read more about Technetium ⁹⁹ᵐTc tilmanocept

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LYMPHOSEEK Kit for radiopharmaceutical preparation	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V09IA09		V Various → V09 Diagnostic radiopharmaceuticals → V09I Tumour detection → V09IA Technetium (99mTc) compounds
Discover more medicines within V09IA09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1669338, 1778463
ES	Centro de información online de medicamentos de la AEMPS	114955001
FR	Base de données publique des médicaments	62978998
GB	Medicines & Healthcare Products Regulatory Agency	356395
IT	Agenzia del Farmaco	043784014, 043784026
LT	Valstybinė vaistų kontrolės tarnyba	1023155, 1084581
PL	Rejestru Produktów Leczniczych	100332779